



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Pharmacy Medical Policy

Injectable Asthma Medications

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Coding Information](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)
- [Forms](#)

Policy Number: 017

BCBSA Reference Number: None

Related Policies

Dupixent (dupilumab) resides in [Medical policy 033](#)

Policy

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity

Note: All requests for outpatient retail pharmacy for indications listed and not listed on the medical policy guidelines may be submitted to BCBSMA Clinical Pharmacy Operations by completing the Prior Authorization Form on the last page of this document. Physicians may also submit requests for exceptions via the web using Express PA which can be found on the BCBSMA provider portal or directly on the web at <https://provider.express-path.com>.

Cinqair[®] (reslizumab) is indicated for the add-on maintenance treatment of patients with severe asthma when **ALL** of the following criteria must be met:

- Patient is ≥ 18 years old, **And**
- Patient is diagnosed with an eosinophilic phenotype, **And**
- CINQAIR is **NOT** indicated for treatment of other eosinophilic conditions, **And**
- CINQAIR is **NOT** indicated for the relief of acute bronchospasm or status asthmaticus.

Fasenra[™] (benralizumab) is indicated for the add-on maintenance treatment of patients with severe asthma when **ALL** of the following criteria must be met:

- Patient is ≥ 12 years old, **And**
- Patient is diagnosed with an eosinophilic phenotype, **And**
- **Fasenra**[™] is **NOT** indicated for treatment of other eosinophilic conditions, **And**
- **Fasenra**[™] is **NOT** indicated for the relief of acute bronchospasm or status asthmaticus.

Nucala[®] (mepolizumab) may be covered when **ALL** of the following criteria must be met:

- add-on maintenance treatment of patients with severe asthma, **And**
 - Patient is ≥ 12 years old, **And**
 - Patient is diagnosed with an eosinophilic phenotype
- Or**
- An adult patient is diagnosed with an eosinophilic granulomatosis with polyangiitis (EGPA).

Xolair™*^ (omalizumab), a recombinant humanized monoclonal anti-immunoglobulin E (IgE) antibody, may be covered for allergic mediated moderate-to-severe asthma caused by perennial aeroallergens, and in accordance with the FDA approved criteria. **ALL** of the following criteria must be met:

- Patient is ≥ 6 years old¹
- Asthma symptoms are not adequately controlled by > 3 months of continuous therapy of high dose inhaled steroids^{1,3} or oral steroids
- Patient has a positive skin test or in vitro testing for one or more perennial aeroallergen
- For pediatric patients between 6 years old and 12 years old recent IgE levels are within the range of 30 to 1300 IU/ml (“recent” is defined as any time prior to treatment but within 6 months)
- For Patients 12 years and older recent IgE levels are within the range of 30 to 700 IU/ml (“recent” is defined as any time prior to treatment but within 6 months)
- Only when prescribed by a pulmonologist or allergist.

Xolair™*^ (omalizumab) also may be covered if **ALL** of the following are met:

- Patient is ≥ 6 years old¹
- Patient has a Diagnosis of Chronic idiopathic urticaria (CIU)
- Symptomatic despite H1 antihistamine treatment
- Only when prescribed by a Dermatologist or Allergist.

Xolair™ (omalizumab) is not covered except for the condition listed above.

*^ - This medication is Part of the Med UM Program.

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member’s contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity:

HCPCS Codes

HCPCS codes:	Code Description
J0517	Injection, benralizumab, 1 mg
J2182	Injection, mepolizumab, 1 mg (Nucala®)
J2357	Injection, omalizumab, 5 mg (Xolair™)
J2786	Injection, reslizumab, 1 mg (Cinqair®)
C9437	Injection, mepolizumab, 1 mg (Nucala®)
J3580	Unclassified biologics (NOC Code)

ICD-10 Diagnosis Codes

ICD-10-CM Diagnosis codes:	Code Description
J45.40	Moderate persistent asthma, uncomplicated
J45.41	Moderate persistent asthma with (acute) exacerbation
J45.42	Moderate persistent asthma with status asthmaticus
J45.50	Severe persistent asthma, uncomplicated
J45.51	Severe persistent asthma with (acute) exacerbation
J45.52	Severe persistent asthma with status asthmaticus

J45.901	Unspecified asthma with (acute) exacerbation
J45.902	Unspecified asthma with status asthmaticus
J45.909	Unspecified asthma, uncomplicated
J45.991	Cough variant asthma
J45.998	Other asthma

Individual Consideration

All our medical policies are written for the majority of people with a given condition. Each policy is based on medical science. For many of our medical policies, each individual's unique clinical circumstances may be considered in light of current scientific literature. Physicians may send relevant clinical information for individual patients for consideration to:

Blue Cross Blue Shield of Massachusetts
 Pharmacy Operations Department
 25 Technology Place
 Hingham, MA 02043
 Tel: 1-800-366-7778
 Fax: 1-800-583-6289

Managed Care Authorization Instructions

- Prior authorization is required for all out patient sites of service
- For all outpatient sites of service, physicians may fax or mail the attached form to the address above.
- For all outpatient sites of service, physicians may also submit authorization requests via the web using Express PAtH which can be found on the BCBSMA provider portal or directly on the web at <https://provider.express-path.com>.

PPO and Indemnity Authorization Instructions

- Prior authorization **is** required when this medication is processed under the home infusion therapy benefit.
- Prior authorization **is not** required when drugs are not part of the Pharmacy only program and are purchased by the physician and administered in the office in accordance with this medical policy.
- Physicians may also fax or mail the attached form to the address above.
- Physicians may also submit authorization requests via the web using Express PAtH which can be found on the BCBSMA provider portal or directly on the web at <https://provider.express-path.com>.

Policy History

Date	Action
1/2019	Clarified coding information.
4/2018	Clarified coding information.
2/2018	Updated to include Fasentra and a new indication for Nucala.
10/2017	Updated to clarify pediatric IgE levels.
6/2017	Update address for Pharmacy Operations.
1/2017	Updated to include New HCPCS/CPT codes.
10/2016	Updated to include CinQair® and allow all three medications to be billed on both Medical & Pharmacy.
6/2016	Updated to include Nucala® to Medical Only and changed the Policy Name.
7/2014	Updated to include ICD-10 and updated with new Indication CIU.
1/2014	Updated ExpressPAtH language.
3/2012	Reviewed – Medical Policy Group - Allergy, Asthma, Immunology and ENT/Otolaryngology. No changes to policy statements.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
3/2011	Reviewed - Medical Policy Group - Allergy and ENT/Otolaryngology. No changes to policy statements.
3/2010	Reviewed - Medical Policy Group - Allergy and ENT/Otolaryngology. No changes to policy statements.

10/2009	Updated to reflect UM guidelines.
3/2009	Reviewed - Medical Policy Group - Allergy and ENT/Otolaryngology. No changes to policy statements.
3/2008	Reviewed - Medical Policy Group - Allergy and ENT/Otolaryngology. No changes to policy statements.
3/2007	Reviewed - Medical Policy Group - Allergy and ENT/Otolaryngology. No changes to policy statements.
9/2003	New policy, effective 9/2003, describing covered and non-covered indications.

References

1. Xolair™ subcutaneous injection [package insert]. South San Francisco, CA and East Hanover, NJ: Genentech, Inc. and Novartis Pharmaceuticals Corporation; June 2003.
2. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. *Eur Respir J.* 2001;18:254-261.
3. Buhl R, Solèr M, Matz J, et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. *Eur Respir J.* 2002;20:73-78.
4. Buhl R, Hanf G, Solèr M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. *Eur Respir J.* 2002;20:1088-1094.
5. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. *J Allergy Clin Immunol.* 2001;108(2):184-190.
6. Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. *J Allergy Clin Immunol.* 2003;111(2):278-284.
7. Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. *Curr Med Res Opin.* 2001;17(4):233-240.
8. Nucala® [package insert]. Philadelphia, PA: GlaxoSmithKline LLC; Nov 2015.
9. Cinqair® [package insert]. Frazer, PA: Teva Pharmaceutical Industries Ltd; Mar 2016.
10. Faserna™ [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; Nov 2017.

To request prior authorization using the Massachusetts Standard Form for Medication Prior Authorization Requests (eForm), click the link below:

http://www.bluecrossma.com/common/en_US/medical_policies/023%20E%20Form%20medication%20prior%20auth%20instruction%20prn.pdf